ATE327236T1 - Desazapurine und deren verwendung - Google Patents

Desazapurine und deren verwendung

Info

Publication number
ATE327236T1
ATE327236T1 AT03729359T AT03729359T ATE327236T1 AT E327236 T1 ATE327236 T1 AT E327236T1 AT 03729359 T AT03729359 T AT 03729359T AT 03729359 T AT03729359 T AT 03729359T AT E327236 T1 ATE327236 T1 AT E327236T1
Authority
AT
Austria
Prior art keywords
inflammatory
generally
desazapurines
subclasses
autoimmune
Prior art date
Application number
AT03729359T
Other languages
English (en)
Inventor
Jane Daun
Heather A Davis
Fabian Gusovsky
Ieharu Hishinuma
Yimin Jiang
Toshihiko Kaneko
Kouichi Kikuchi
Seiichi Kobayashi
Andre Lescarbeau
Xiang-Yi Li
Kenzo Muramoto
Norihito Ohi
Marc Pesant
Boris M Seletsky
Motohiro Soejima
Ye Yao
Hiromitsu Yokohama
Yan J Zhao
Wanjun Zheng
Lynda Tremblay
Bruce F Decosta
Mark Spyvee
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE327236T1 publication Critical patent/ATE327236T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03729359T 2002-01-07 2003-01-07 Desazapurine und deren verwendung ATE327236T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34659802P 2002-01-07 2002-01-07

Publications (1)

Publication Number Publication Date
ATE327236T1 true ATE327236T1 (de) 2006-06-15

Family

ID=23360154

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03729359T ATE327236T1 (de) 2002-01-07 2003-01-07 Desazapurine und deren verwendung

Country Status (22)

Country Link
US (4) US7314936B2 (de)
EP (2) EP1474425B9 (de)
JP (1) JP4411455B2 (de)
KR (2) KR101108722B1 (de)
CN (1) CN100503608C (de)
AT (1) ATE327236T1 (de)
AU (2) AU2003235741B8 (de)
BR (1) BR0306785A (de)
CA (1) CA2472479C (de)
CY (1) CY1106138T1 (de)
DE (2) DE60305446D1 (de)
DK (1) DK1474425T3 (de)
ES (1) ES2262996T3 (de)
IL (3) IL162884A0 (de)
MX (1) MXPA04006614A (de)
NO (1) NO329994B1 (de)
NZ (2) NZ533958A (de)
PT (1) PT1474425E (de)
RU (1) RU2380368C2 (de)
SI (1) SI1474425T1 (de)
WO (1) WO2003057696A1 (de)
ZA (1) ZA200406272B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
EP1474425B9 (de) * 2002-01-07 2008-07-02 Eisai Co., Ltd. Desazapurine und deren verwendung
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
US7655800B2 (en) 2005-02-02 2010-02-02 Eisai R & D Management Co., Ltd. Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007125315A2 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
US8507473B2 (en) * 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
CA2811025C (en) 2010-09-10 2018-07-17 Shionogi & Co., Ltd. Hetero ring-fused imidazole derivative having ampk activating effect
MX348131B (es) * 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
WO2012131399A1 (en) 2011-04-01 2012-10-04 Astrazeneca Ab Therapeutic treatment
GB201106814D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
WO2013011932A1 (ja) 2011-07-15 2013-01-24 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するアザベンズイミダゾール誘導体
PT2785349T (pt) 2011-11-30 2019-12-11 Astrazeneca Ab Tratamento combinado de cancro
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
GB201401198D0 (en) * 2014-01-24 2014-03-12 Bial Portela & Ca Sa Process for the syntheis of substituted urea compounds
EP2913330A1 (de) 2014-02-27 2015-09-02 Laboratoire Biodim Als Arzneimittel geeignete kondensierte Derivate von Imidazol
CN104974187A (zh) * 2014-04-10 2015-10-14 吉林省博创药业有限公司 菲罗啉类衍生物及其制备方法和应用
CN107001362A (zh) * 2014-10-06 2017-08-01 默克专利有限公司 用作btk抑制剂的杂芳基化合物及其用途
EP3562487B1 (de) 2016-12-29 2023-11-29 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzym-inhibitor-verbindungen
EP3562306B1 (de) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzym-inhibitor-verbindungen
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
WO2019099336A1 (en) 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
AU2018386201A1 (en) 2017-12-15 2020-07-30 Bristol-Myers Squibb Company Substituted indole ether compounds
CN111511730B (zh) * 2017-12-19 2023-07-25 百时美施贵宝公司 可用作tlr抑制剂的被酰胺取代的吲哚化合物
US11878975B2 (en) * 2017-12-19 2024-01-23 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
SG11202005704RA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co 6-azaindole compounds
SG11202005694RA (en) * 2017-12-20 2020-07-29 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors
CA3085937A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
US11998537B2 (en) 2018-10-24 2024-06-04 Bristol-Myers Squibb Company Substituted indole dimer compounds
WO2020086503A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CN114269383A (zh) 2019-01-08 2022-04-01 菲斯生物制药公司 金属酶抑制剂化合物
KR102904576B1 (ko) 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
ES2965164T3 (es) 2019-10-04 2024-04-11 Bristol Myers Squibb Co Compuestos de carbazol sustituidos

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891660A (en) * 1974-02-07 1975-06-24 Squibb & Sons Inc Derivatives of 1H-imidazo{8 4,5-c{9 pyridine-7-carboxylic acids and esters
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US4939146A (en) * 1987-01-29 1990-07-03 Kramer Richard S Method for alleviating ischemic-reperfusion injury
DE3702757A1 (de) 1987-01-30 1988-08-11 Hoechst Ag Neue imidazo- und triazolo-thiadiazine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung, sowie einige bei der herstellung der genannten verbindungen gebildete zwischenprodukte
US4999365A (en) * 1987-03-20 1991-03-12 Merrell Dow Pharmaceuticals Inc. Method of reducing reperfusion injury with imidazol-2-thiones
US4877810A (en) * 1988-02-05 1989-10-31 Eastman Kodak Company Protection of heart tissue from reperfusion injury
US5632991A (en) 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
US5002965A (en) * 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
US5298518A (en) 1989-09-29 1994-03-29 Eisai Co., Ltd. Biphenylmethane derivative and pharmacological use
SE8904355D0 (sv) 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5081253A (en) 1989-12-21 1992-01-14 American Home Products Corporation Imidazo(4,5-c)pyridines as antiosteoporotic agents
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
ATE157665T1 (de) 1992-06-22 1997-09-15 Boehringer Ingelheim Kg 9-amino-pyridazino 4',5' : 3,4>pyrrolo- 2,1- a>isochinoline und deren verwendung für die herstellung von pharmazeutischen zubereitungen
US5591835A (en) * 1992-06-29 1997-01-07 Glycomed Incorporated Substituted lactose derivatives
US5360794A (en) 1992-08-03 1994-11-01 Medicarb Inc. Disubstituted and deoxy disubstituted derivatives of α-D-mannofuranosides and β-L-gulofuranosides having anti-inflammatory and anti-proliferative activity
GB9313638D0 (en) 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CA2229438C (en) * 1995-11-22 2006-01-17 Chiroscience Limited Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf)
US5981536A (en) 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
JPH10139709A (ja) 1996-11-13 1998-05-26 Chisso Corp フェニルポリハロアルキルエーテル誘導体、これを含む液晶組成物および液晶表示素子
JP3410476B2 (ja) * 1997-04-18 2003-05-26 大鵬薬品工業株式会社 新規なエポキシコハク酸アミド誘導体又はその塩
JP2002507996A (ja) 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
AU751573C (en) 1998-03-27 2003-10-09 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
KR100718830B1 (ko) 1999-06-23 2007-05-17 사노피-아벤티스 도이칠란트 게엠베하 치환된 벤즈이미다졸 및 이의 제조방법
HK1045507A1 (zh) * 1999-08-12 2002-11-29 Vertex Pharmaceuticals Incorporated C-jun n-末端激酶(jnk)及其他蛋白质激酶的抑制物
CA2300328A1 (en) 1999-09-14 2001-03-14 Cardiogene Gentherap. Systeme Ag Modulating transcription of genes in vascular cells
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
AU7922900A (en) * 1999-10-27 2001-05-08 Novartis Ag Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
EP1256582A1 (de) 2000-02-09 2002-11-13 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridin-derivate
US7186683B2 (en) * 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
AU2002308748A1 (en) * 2001-05-16 2002-11-25 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
KR20050044660A (ko) * 2001-12-04 2005-05-12 에프. 호프만-라 로슈 아게 치환된 2-아미노-사이클로알칸카복스아마이드 및 시스테인프로테아제 저해제로서의 이의 용도
EP1474425B9 (de) * 2002-01-07 2008-07-02 Eisai Co., Ltd. Desazapurine und deren verwendung
US6861278B2 (en) * 2002-04-11 2005-03-01 Nordson Corporation Method and apparatus for underfilling semiconductor devices
US7655800B2 (en) * 2005-02-02 2010-02-02 Eisai R & D Management Co., Ltd. Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses

Also Published As

Publication number Publication date
KR20040077707A (ko) 2004-09-06
CN1630657A (zh) 2005-06-22
US20050124649A1 (en) 2005-06-09
IL197484A0 (en) 2009-12-24
US20040186127A1 (en) 2004-09-23
AU2003235741B8 (en) 2009-01-15
EP1474425B9 (de) 2008-07-02
DK1474425T3 (da) 2006-09-25
MXPA04006614A (es) 2004-10-04
AU2003235741B2 (en) 2008-12-04
NO20043290D0 (no) 2004-08-06
US7314936B2 (en) 2008-01-01
SI1474425T1 (sl) 2006-10-31
CA2472479C (en) 2011-10-11
DE60305446T2 (de) 2007-03-08
WO2003057696A1 (en) 2003-07-17
JP2005524621A (ja) 2005-08-18
DE60305446D1 (de) 2006-06-29
NO329994B1 (no) 2011-02-07
CA2472479A1 (en) 2003-07-17
RU2004124054A (ru) 2005-04-10
KR101108722B1 (ko) 2012-02-17
CN100503608C (zh) 2009-06-24
KR100980163B1 (ko) 2010-09-03
EP1474425B1 (de) 2006-05-24
PT1474425E (pt) 2006-09-29
ZA200406272B (en) 2006-01-25
NZ555911A (en) 2008-07-31
US8691814B2 (en) 2014-04-08
EP1474425A1 (de) 2004-11-10
IL191543A0 (en) 2008-11-03
IL162884A0 (en) 2005-11-20
ES2262996T3 (es) 2006-12-01
JP4411455B2 (ja) 2010-02-10
NO20043290L (no) 2004-09-22
AU2009200689A1 (en) 2009-03-12
AU2003235741A1 (en) 2003-07-24
KR20100066593A (ko) 2010-06-17
EP1707566A1 (de) 2006-10-04
CY1106138T1 (el) 2011-06-08
DE60305446T4 (de) 2009-07-09
US20110105427A1 (en) 2011-05-05
US7868002B2 (en) 2011-01-11
US20080103137A1 (en) 2008-05-01
BR0306785A (pt) 2004-11-09
NZ533958A (en) 2007-09-28
RU2380368C2 (ru) 2010-01-27

Similar Documents

Publication Publication Date Title
DE60305446D1 (de) Desazapurine und deren verwendung
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
ATE335748T1 (de) Thienopyrimidindione und deren verwendung bei der modulierung von autoimmunerkrankungen
ATE383358T1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
ATE496884T1 (de) Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
DK0842934T3 (da) 5-HT1F agonister
MY136800A (en) Inhibitors of the interaction between mdm2 and p53
DE602005023963D1 (de) Weitere heteropolycyclische verbindungen und deren verwendung als antagonisten des metabotropen glutamatrezeptors
ATE346058T1 (de) Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon
ATE369372T1 (de) 42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
ATE447562T1 (de) Verstärker von glutamat-rezeptoren
DE60305484D1 (de) Verbindungen und deren verwendung als 5-ht inhibitore
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
DE602004031410D1 (de) Inden derivate als pharmazeutika
SE0303280D0 (sv) Novel compounds
ATE315563T1 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
NO20002408D0 (no) 5-HT1F antagonister
SE0302755D0 (sv) Novel compounds
ATE530552T1 (de) Pyrrolobenzimidazolone und deren verwendung als antiproliferative mittel
ATE448223T1 (de) 8-azabicycloä3.2.1üoctanderivate und ihre verwendung als monoamine-neurotransmitter- reuptake inhibitoren
ATE324368T1 (de) Heteroarylheteroalkylamin derivate und deren verwendung als inhibitoren der stickoxidsynthase
IL173629A0 (en) Imidazo(4,5-b) pyridine derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1474425

Country of ref document: EP

EEIH Change in the person of patent owner